ERBB2 and breast cancer: Phase I/II clinical trials are currently recruiting patients to test the benefit of combining Tociluzumab with various immunotherapies for the treatment of late-stage melanoma (NCT03999749), prostate cancer (NCT03821246), and metastatic HER2-positive breast cancer (NCT03135171).